ClinicalTrials.gg
Enrolling by invitationNCT06410768Updated May 13, 2024

Economic Evaluation of a Multistage Shared Decision-making Program for Type 2 Diabetes: a Pilot Study

An interventional study of multistage shared decision-making program in Diabetes Mellitus, Type 2, sponsored by Maastricht University Medical Center. Enrolling by invitation at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center — 2 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Maastricht University Medical Center.

Planned enrollment
13th of 36
40 · median 31
Started
2024
with 2 others
No phase
34 of 40
2 open now
Registered
38th of 40
by date

Among the 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center, this one is the 13th largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2024, is one of 34 with no phase, and was the 38th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Diabetes Mellitus, Type 2 by Maastricht University Medical Center, or all of them as a file.
02

Study summary

Type 2 diabetes mellitus is a highly prevalent disease, affecting over a million Dutch citizens, leading to severe micro- and macrovascular complications, reduced quality of life, and high healthcare costs. Clinical guidelines recommend a person-centered approach to improve (health)outcomes. However, with rapidly increasing treatment options, both in terms of medication and lifestyle interventions, shared decision making (SDM) is challenging in practice. Therefore, researchers have developed a multistage SDM program consisting of an online patient decision aid for type 2 diabetes mellitus, training for healthcare professionals in SDM, and a preparatory consult to provide patients with the knowledge and confidence to participate in SDM. Strong evidence of (cost)-effectiveness is a key requirement to achieve broad implementation of this program. This pilot study represents an important initial step towards high-quality economic evaluation research, with a focus on the diversity of the study population, burden on participating healthcare practices, and feasibility of outcome measurement.

Read the detailed description

Rationale: Previous randomized controlled trials researching the effects of shared decision-making (SDM) support through patient decision aids (PDAs) for type 2 diabetes mellitus (T2DM) experienced several challenges related to study procedures, resources, and study management. These challenges include difficulties in recruiting participants, understandability of questionnaires, timely recruitment, and inadvertent recruitment bias. Small-scale piloting is crucial to address uncertainties around the feasibility of trial methods and to refine the study procedures of a large-scale economic evaluation. This protocol outlines a pilot study aimed at evaluating the feasibility of a future trial-based economic evaluation of a multistage SDM program, including a PDA for T2DM in the Netherlands. By conducting a pilot study, the researchers aim to improve the quality of the intended trial-based economic evaluation.

Objectives: Researchers will conduct a pilot study focused on the following questions to prepare for an intended economic evaluation of our multistage SDM program for T2DM: 1) How to recruit and retain a representative sample of patients with T2DM in terms of sociodemographic and clinical background?; 2) How to support primary care practices in managing the challenges associated with study participation?; 3) How to feasibly measure relevant outcomes of SDM for T2DM using valid and reliable measurement instruments?

Study design: The multistage SDM program will be piloted in a cluster-randomized controlled trial using a mixed-methods approach. Four primary care practices will be included, of which two will be randomly assigned to the intervention group and two to the control group.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • type 2 diabetes mellitus
  • person-centered care
  • shared decision-making
  • pilot study
  • patient decision aid
  • economic evaluation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is diagnosed with type 2 diabetes mellitus
  • Eighteen years or older
  • Need to decide on type 2 diabetes treatment based on the national guidelines
  • Multiple treatment options (medication and/or lifestyle) are possible as judged by the healthcare professional
  • Speak Dutch at a necessary level to complete questionnaires and ensure involvement in shared decision-making

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairments that hamper shared decision-making
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Intervention

    The intervention entails a multistage shared decision-making (SDM) program for type 2 diabetes mellitus (T2DM) that combines (1) an online PDA with (2) a preparatory consult for patients, and (3) interprofessional training in the PDA and SDM for healthcare professionals.

    Behavioral: multistage shared decision-making program

  • No intervention
    Control

    Patients and healthcare professionals in the control practices will provide and receive usual care according to the national guidelines for T2DM of the Dutch College of General Practitioners (NHG). Participants in the control practices will not have access to the multistage SDM program.

Interventions

  • Behavioralmultistage shared decision-making program

    The multistage shared decision-making program consists of 1) an online patient decision aid; 2) preparatory consult to provide patients with the knowledge and confidence to participate in shared decision-making; and 3) training to improve healthcare professionals' skills for shared decision-making.

06

What researchers measure

Primary outcomes

  1. Sample recruitment

    Recruitment rates: how many patients were recruited on average for one month at one location. Time required to recruit to the target Sociodemographic and clinical characteristics

    Time frame: 9 months

  2. Sample retention

    Retention rates: percentage of participants who completed the study

    Time frame: 9 months

  3. Consent rates

    Consent rates: number of patients enrolled divided by number of eligible patients

    Time frame: 9 months

  4. Recruit to target

    Time required to recruit to target sample size

    Time frame: 9 months

  5. Age (years)

    Age of participating patients in years. Patients are asked to complete a questionnaire at baseline that includes a question regarding their age.

    Time frame: Measured at baseline

  6. Sex (self-reported questionnaire)

    Sex of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding their sex.

    Time frame: Measured at baseline

  7. Country of birth (self-reported questionnaire)

    Country of birth of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding their country of birth.

    Time frame: Measured at baseline

  8. Educational level (self-reported questionnaire)

    Educational level of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding their highest received diploma.

    Time frame: Measured at baseline

  9. Financial (self-reported questionnaire)

    Make ends meet financially of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding their financial situation (i.e. whether they have (not) difficulties in making ends meet financially)

    Time frame: Measured at baseline

  10. Work situation (self-reported questionnaire)

    Work situation of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding their work situation.

    Time frame: Measured at baseline

  11. Duration of type 2 diabetes (self-reported questionnaire)

    Duration of diabetes of participating patients. Patients are asked to complete a questionnaire at baseline that includes a question regarding how many years they have type 2 diabetes.

    Time frame: Measured at baseline

  12. Weight (kg) (self-reported questionnaire)

    Weight of participating patients in kg. Patients are asked to complete a questionnaire at baseline that includes a question regarding what their weight in kg is. This measure is used, in combination with height, to calculate their BMI.

    Time frame: Measured at baseline

  13. Height (cm) (self-reported questionnaire)

    Height of participating patients in kg. Patients are asked to complete a questionnaire at baseline that includes a question regarding what their height in cm is. This measure is used, in combination with weight, to calculate their BMI.

    Time frame: Measured at baseline

  14. Medication use (self-reported questionnaire)

    Medication use of participating patients in kg. Patients are asked to complete a questionnaire at baseline that includes a question regarding whether they use medication, and if so, whether they take oral medication or inject insulin.

    Time frame: Measured at baseline

  15. Medication adherence measured with the Medication Adherence Report Scale (MARS)

    Medication adherence measured with the Medication Adherence Report Scale (MARS) test. This test contains six statements regarding medication adherence and patients are asked to indicate whether the statements applies to them on a five point Likert Scale. Patients are asked to complete this test at baseline, 3 months and 9 months follow-up.

    Time frame: Baseline, 3-months and 9-months follow-up

  16. Health literacy (self-reported questionnaire)

    Health literacy of participating patients measured with the shortened version of the European Health Literacy Survey questionnaire (HLS-EU) Dutch questionnaire (6 questions)

    Time frame: Measured at baseline

  17. Study management measured by conducting focus groups with participating healthcare professionals

    Assessment of primary care practices' study management challenges (i.e. time constraints and capacity issues). This will be assessed by conducting focus groups with healthcare professionals from the participating general practices.

    Time frame: Focus groups will be held at the end of patient inclusion period, 9-months

  18. Patient decisional conflict measured with the decisional conflict scale (DCS)

    Decisional conflict measured with the 16-item decisional conflict scale (DCS). Patients will be asked to reflect on the treatment decision they made with their healthcare professional and respond to 16 statements in the DCS using a five-point Likert scale (ranging from completely agree to completely disagree). Besides a total score, the DCS includes five dimensions (i.e. information, support, clarification or values, certainty, and decision quality) with higher scores on a five-point scale indicating more decisional conflict. Patients are asked to complete this questionnaire at baseline, 3 months and 9 months follow-up.

    Time frame: Throughout implementation period, 9-months

  19. Patient-rated level of shared decision-making measured with the 3-item CollaboRATE survey

    Patient-rated level of shared decision-making is measured by the 3-item CollaboRATE survey. The CollaboRATE survey assesses patients' perception of being informed and engaged in the decision-making steps on a scale of zero (no effort was made) to nine (every effort was made). Patients are asked to complete this questionnaire at baseline, 3 months and 9 months follow-up.

    Time frame: Throughout implementation period, 9-months

  20. Patient-rated level of shared decision-making measured with the SDM-Q-9 questionnaire

    Patient-rated level of shared decision-making is measured by the SDM-Q-9 questionnaire. The SDM-Q-9 questionnaire measures the extent of shared decision-making durin a consultation between the patient and healthcare professional. This questionnaire consists of nine statements each describing a different step of the shared decision-making process. All items are scored on a six-point Likert scale from zero (completely disagree) to five (completely agree).

    Time frame: Throughout implementation period, 9-months

  21. Healthcare professional level of shared decision-making measured with the SDM-Q-Doc questionnaire

    The SDM Q-Doc questionnaire (SDM-Q-9 adapted to the healthcare professional viewpoint) is used to measure the level of shared decision-making during a consultation from the perspective of a healthcare professional.

    Time frame: Throughout implementation period, 9-months

  22. Patient knowledge measured with tailor-made questions

    Patient knowledge is measured with nine tailor-made multiple-choice questions assessing patients' understanding of the (risks and benefits of) glucose-lowering treatments.

    Time frame: Measured at baseline

  23. Glycemic control obtained from general practitioner data

    Glycemic control of participating patients will be obtained by obtaining HbA1c data from the general practitioner

    Time frame: Baseline, 3-months and 9-months follow-up

  24. Health-related quality of life measured with the EuroQol (EQ) 5 Dimension (5D) - 5 Level (5L) questionnaire

    Health-related quality of life of participating patients will be measured with the Dutch EuroQol (EQ) 5 Dimension (5D) - 5 Level (5L) This measure facilitates utility calculations and includes the EQ-5D dimension and the EQ visual analog scale (EQ VAS). EQ-5D comprises five dimensions: mobility, self-care, pain, usual activities and anxiety. Each dimension is scored on a five-point Likert score (from no problems to extreme problems). The EQ VAS is used to assess the patient's self-reported health on a visual analog scale.

    Time frame: Baseline, 3-months and 9-months follow-up

  25. Medical consumption measured with the iMCQ

    Medical consumption will be measured with an adapted version of the institute for Medical technology Assessment (iMTA) Medical Consumption Questionnaire (iMCQ).

    Time frame: Baseline, 3-months and 9-months follow-up

  26. Productivity costs measured with the iPCQ

    Productivity costs will be measured with an adapted version of the institute for Medical technology Assessment (iMTA) Productivity Costs Questionnaire (iPCQ).

    Time frame: Baseline, 3-months and 9-months follow-up

  27. Understandability of measurement tools

    Sem-structured interviews with patients will be held to gain insight into the understandability of the measurement tools.

    Time frame: Throughout the 9-month implementation period

07

Study locations

1 site
  • Care group Huisarts & Zorg
    Gorinchem, Netherlands
08

References and documents

Publications

  • Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, Thomson R, Barratt A, Barry M, Bernstein S, Butow P, Clarke A, Entwistle V, Feldman-Stewart D, Holmes-Rovner M, Llewellyn-Thomas H, Moumjid N, Mulley A, Ruland C, Sepucha K, Sykes A, Whelan T; International Patient Decision Aids Standards (IPDAS) Collaboration. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006 Aug 26;333(7565):417. doi: 10.1136/bmj.38926.629329.AE. Epub 2006 Aug 14. PubMed 16908462 ↗
  • ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S140-S157. doi: 10.2337/dc23-S009. PubMed 36507650 ↗
  • Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022 Dec;65(12):1925-1966. doi: 10.1007/s00125-022-05787-2. Epub 2022 Sep 24. PubMed 36151309 ↗
  • Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC): National Academies Press (US); 2001. Available from http://www.ncbi.nlm.nih.gov/books/NBK222274/ PubMed 25057539 ↗
  • Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L, Wu JH. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014 Jan 28;(1):CD001431. doi: 10.1002/14651858.CD001431.pub4. PubMed 24470076 ↗
  • Stacey D, Suwalska V, Boland L, Lewis KB, Presseau J, Thomson R. Are Patient Decision Aids Used in Clinical Practice after Rigorous Evaluation? A Survey of Trial Authors. Med Decis Making. 2019 Oct;39(7):805-815. doi: 10.1177/0272989X19868193. Epub 2019 Aug 17. PubMed 31423911 ↗
  • Kellar I, Mann E, Kinmonth AL, Prevost AT, Sutton S, Marteau TM. Can informed choice invitations lead to inequities in intentions to make lifestyle changes among participants in a primary care diabetes screening programme? Evidence from a randomized trial. Public Health. 2011 Sep;125(9):645-52. doi: 10.1016/j.puhe.2011.05.010. Epub 2011 Jul 20. PubMed 21764087 ↗
  • Branda ME, LeBlanc A, Shah ND, Tiedje K, Ruud K, Van Houten H, Pencille L, Kurland M, Yawn B, Montori VM. Shared decision making for patients with type 2 diabetes: a randomized trial in primary care. BMC Health Serv Res. 2013 Aug 8;13:301. doi: 10.1186/1472-6963-13-301. PubMed 23927490 ↗
  • Mathers N, Ng CJ, Campbell MJ, Colwell B, Brown I, Bradley A. Clinical effectiveness of a patient decision aid to improve decision quality and glycaemic control in people with diabetes making treatment choices: a cluster randomised controlled trial (PANDAs) in general practice. BMJ Open. 2012 Nov 5;2(6):e001469. doi: 10.1136/bmjopen-2012-001469. Print 2012. PubMed 23129571 ↗
  • Mullan RJ, Montori VM, Shah ND, Christianson TJ, Bryant SC, Guyatt GH, Perestelo-Perez LI, Stroebel RJ, Yawn BP, Yapuncich V, Breslin MA, Pencille L, Smith SA. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med. 2009 Sep 28;169(17):1560-8. doi: 10.1001/archinternmed.2009.293. PubMed 19786674 ↗
  • Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, Robson R, Thabane M, Giangregorio L, Goldsmith CH. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010 Jan 6;10:1. doi: 10.1186/1471-2288-10-1. Erratum In: BMC Med Res Methodol. 2023 Mar 11;23(1):59. doi: 10.1186/s12874-023-01880-1. PubMed 20053272 ↗
  • van Teijlingen E, Hundley V. The importance of pilot studies. Nurs Stand. 2002 Jun 19-25;16(40):33-6. doi: 10.7748/ns2002.06.16.40.33.c3214. PubMed 12216297 ↗
  • Black SA. Diabetes, diversity, and disparity: what do we do with the evidence? Am J Public Health. 2002 Apr;92(4):543-8. doi: 10.2105/ajph.92.4.543. PubMed 11919048 ↗
  • Brodaty H, Gibson LH, Waine ML, Shell AM, Lilian R, Pond CD. Research in general practice: a survey of incentives and disincentives for research participation. Ment Health Fam Med. 2013 Sep;10(3):163-73. PubMed 24427184 ↗
  • McKinley N, McCain RS, Convie L, Clarke M, Dempster M, Campbell WJ, Kirk SJ. Resilience, burnout and coping mechanisms in UK doctors: a cross-sectional study. BMJ Open. 2020 Jan 27;10(1):e031765. doi: 10.1136/bmjopen-2019-031765. PubMed 31988223 ↗
  • West CP, Dyrbye LN, Shanafelt TD. Physician burnout: contributors, consequences and solutions. J Intern Med. 2018 Jun;283(6):516-529. doi: 10.1111/joim.12752. Epub 2018 Mar 24. PubMed 29505159 ↗
  • Tichler A, Hertroijs DFL, Ruwaard D, Brouwers MCGJ, Hiligsmann M, de Jong JD, Elissen AMJ. Preferred Conversation Topics with Respect to Treatment Decisions Among Individuals with Type 2 Diabetes. Patient Prefer Adherence. 2023 Mar 17;17:719-729. doi: 10.2147/PPA.S397647. eCollection 2023. PubMed 36960182 ↗
  • Legare F, Ratte S, Gravel K, Graham ID. Barriers and facilitators to implementing shared decision-making in clinical practice: update of a systematic review of health professionals' perceptions. Patient Educ Couns. 2008 Dec;73(3):526-35. doi: 10.1016/j.pec.2008.07.018. Epub 2008 Aug 26. PubMed 18752915 ↗

Individual participant data

Plan to share: Yes — The study protocol will be made publicly available as a research article in a scientific journal. The protocol is under review.

Supporting information: Study protocol

Time frame: The study protocol will be made publicly available as a research article in a scientific journal. The protocol is under review (April 2024).

Access criteria: There will be no access criteria for the protocol (open access publication)

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Nov 2024, 9 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 9 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
May 13, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Nov 1, 2024
CompletionEst.
May 1, 2025
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06410768
Collaborators
Maastricht University
Responsible party
Sponsor
First posted
May 13, 2024
Start date
Feb 1, 2024
Primary completion
Nov 1, 2024 (estimated)
Completion
May 1, 2025 (estimated)
Last update
May 13, 2024

Study contacts

Arianne Elissen, PhD
principal investigator · Maastricht University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion